Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Spark Therapeutics

- PMLiVE

Pfizer buys gene therapy specialist Bamboo

Expands pipeline with Duchenne muscular dystrophy candidate in deal worth $700m

Harnessing complexity

Companion diagnostics in oncology

- PMLiVE

Mixed news for gene therapies at ASH conference

GSK unveils successful trial, but there was disappointing news for Bluebird

- PMLiVE

Spark set to file eye disease gene therapy next year

SPK-RPE65 shows significant benefit in functional vision for patients with retinal dystropies

Biogen Idec building

Biogen Idec taps Sangamo for blood disorder drugs

Deal is worth up to $320m

- PMLiVE

Boehringer backs gene therapy firm Eyevensys

Invests in French eye disease specialist

- PMLiVE

Basilea’s Hans Christian Rohde takes up commercial role at uniQure

Will serve as gene therapy specialist's chief commercial officer

- PMLiVE

Gene therapy: the promise comes closer

After decades of development and a trail of failed clinical trials, gene therapy is finally emerging as a worthwhile approach for treating a range of acquired and inherited diseases

Novartis building

Novartis signs $665m option deal with Selexys

Would acquire biotech company and its sickle cell disease drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links